{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:48:33Z","timestamp":1767142113256,"version":"build-2238731810"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,6,12]],"date-time":"2017-06-12T00:00:00Z","timestamp":1497225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s11064-017-2312-y","type":"journal-article","created":{"date-parts":[[2017,6,11]],"date-time":"2017-06-11T23:35:50Z","timestamp":1497224150000},"page":"2084-2088","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Genomics-Guided Precise Anti-Epileptic Drug Development"],"prefix":"10.1007","volume":"42","author":[{"given":"Norman","family":"Delanty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpiero","family":"Cavallleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,12]]},"reference":[{"key":"2312_CR1","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/j.1528-1167.2012.03511.x","volume":"53","author":"Epi4K Consortium","year":"2012","unstructured":"Epi4K Consortium (2012) Epi4K: Gene discovery in 4000 genomes. Epilepsia 53:1457\u20131467","journal-title":"Epilepsia"},{"key":"2312_CR2","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S1474-4422(15)00199-4","volume":"14","author":"EpiPM Consortium","year":"2015","unstructured":"EpiPM Consortium (2015) A road map for precision medicine in the epilepsies. Lancet Neurol 14:1219\u20131228","journal-title":"Lancet Neurol"},{"key":"2312_CR3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/14737175.2017.1253476","volume":"17","author":"PS Reif","year":"2016","unstructured":"Reif PS, Tsai M-H, Helbig I et al (2016) Precision medicine in genetic epilepsies: break of dawn? Exp Rev. Neurother 17:381\u2013392","journal-title":"Exp Rev. Neurother"},{"key":"2312_CR4","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.phrs.2016.04.006","volume":"107","author":"P Striano","year":"2016","unstructured":"Striano P, Vari MS, Mazzocchetti C et al (2016) Management of genetic epilepsies: from empirical treatment to precision medicine. Pharm Res 107:426\u2013429","journal-title":"Pharm Res"},{"issue":"9","key":"2312_CR5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S1474-4422(14)70171-1","volume":"13","author":"International League Against Epilepsy Consortium on Complex Epilepsies","year":"2014","unstructured":"International League Against Epilepsy Consortium on Complex Epilepsies (2014) Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. Lancet Neurology 13(9):893\u2013903","journal-title":"Lancet Neurology"},{"issue":"12","key":"2312_CR6","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","volume":"364","author":"M McCormack","year":"2011","unstructured":"McCormack M, Alfirevic A, Bourgeois S et al (2011) HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. New Engl J Med 364(12):1134\u20131143","journal-title":"New Engl J Med"},{"key":"2312_CR7","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","volume":"364","author":"P Chen","year":"2011","unstructured":"Chen P, Lin J-J, Lu C-S et al (2011) Carbamazepine-induced toxic effects and HLA B*1502 screening in Taiwan. New Engl J Med 364:1126\u20131133","journal-title":"New Engl J Med"},{"key":"2312_CR8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature12439","volume":"501","author":"Epi4k Consortium","year":"2013","unstructured":"Epi4k Consortium (2013) Epilepsy Phenome\/Genome Project. De novo mutations in epileptic encephalopthies. Nature 501:217\u2013221","journal-title":"Nature"},{"key":"2312_CR9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ajhg.2014.08.013","volume":"95","author":"RES Consortium, Epilepsy Phenome\/Genome P, Epi4K Consortium","year":"2014","unstructured":"EuroEPINOMICS-RES Consortium, Epilepsy Phenome\/Genome P, Epi4K Consortium (2014) De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. Am J Hum Genet 95:360\u2013370","journal-title":"Am J Hum Genet"},{"key":"2312_CR10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ajhg.2016.06.003","volume":"99","author":"Epi4k Consortium","year":"2016","unstructured":"Epi4k Consortium (2016) De Novo mutations in SLC1A2 and CACNA1A are important causes of epileptic encephalopathies. Am J Hum Genet 99:287\u2013298","journal-title":"Am J Hum Genet"},{"key":"2312_CR11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1474-4422(16)30359-3","volume":"16","author":"Epi4k Consortium","year":"2017","unstructured":"Epi4k Consortium (2017) Epilepsy Phenome\/Genome Project. Ultra-rare genetic variation in common epilepsies: a case-control sequencing study. Lancet Neurol 16:135\u2013143","journal-title":"Lancet Neurol"},{"key":"2312_CR12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11910-015-0587-4","volume":"15","author":"R Dhindsa","year":"2015","unstructured":"Dhindsa R, Goldstein DB (2015) Genetic discoveries drive molecular analyses and targeted therapeutic options in the epilepsies. Curr Neurol Neurosci Rep 15:70","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2312_CR13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrneurol.2016.81","volume":"12","author":"PB Crino","year":"2016","unstructured":"Crino PB (2016) The mTOR signaling cascade: paving new roads to cure neurological disease. Nat Rev Neurol 12:379\u2013392","journal-title":"Nat Rev Neurol"},{"key":"2312_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/TACG.S90262","volume":"10","author":"C Caban","year":"2017","unstructured":"Caban C, Khan N, Hasbani DM, Crino PB (2017) Genetics of tuberous sclerosis complex: implications for clinical practice. Appl Clin Genet 10:1\u20138","journal-title":"Appl Clin Genet"},{"key":"2312_CR15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","volume":"372","author":"P Curatolo","year":"2008","unstructured":"Curatolo P, Bombardieri R, Joswiak S (2008) Tuberous sclerosis. Lancet 372:657\u2013668","journal-title":"Lancet"},{"key":"2312_CR16","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.febslet.2011.02.001","volume":"585","author":"JM Han","year":"2011","unstructured":"Han JM, Sahin M (2011) TSC1\/TSC2 signalling in the CNS. FEBS Lett 585:973\u2013980","journal-title":"FEBS Lett"},{"key":"2312_CR17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.phrs.2016.03.039","volume":"107","author":"R Citraro","year":"2016","unstructured":"Citraro R et al (2016) mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. Pharmacol Res 107:333\u2013343","journal-title":"Pharmacol Res"},{"key":"2312_CR18","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA, Lawson JA, Yapici Z et al (2016) Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase three, randomized, double-blind, placebo controlled study. Lancet 388:2153\u20132163","journal-title":"Lancet"},{"key":"2312_CR19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ana.24547","volume":"79","author":"MG Ricos","year":"2016","unstructured":"Ricos MG, Hodgson BL, Pippucci T et al (2016) Mutations in the mammalian target of rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy. Ann Neurol 79:120\u2013131","journal-title":"Ann Neurol"},{"key":"2312_CR20","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/epi.13391","volume":"57","author":"S Weckhuysen","year":"2016","unstructured":"Weckhuysen S, Marson E, Lambrecq V et al (2016) Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia. Epilepsia 57:994\u20131003","journal-title":"Epilepsia"},{"key":"2312_CR21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1136\/jmedgenet-2016-103883","volume":"53","author":"S Baldassari","year":"2016","unstructured":"Baldassari S, Licchetta L, Truper P et al (2016) GATOR1 complex: the common genetic actor in focal epilepsies. J Med Genet 53:503\u2013510","journal-title":"J Med Genet"},{"key":"2312_CR22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ana.24128","volume":"75","author":"CJ Milligan","year":"2014","unstructured":"Milligan CJ, Li M, Gazina Ev et al (2014) KCNT1 gain of function in two epilepsy phenotypes is reversed by quinidine. Ann Neurol 75:581\u2013590","journal-title":"Ann Neurol"},{"key":"2312_CR23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ana.24229","volume":"76","author":"D Beardon","year":"2014","unstructured":"Beardon D, Strong A, Ehnot J et al (2014) Targeted treatment of migrating partial seizures of infancy with quinidine. Ann Neurol 76:457\u2013461","journal-title":"Ann Neurol"},{"key":"2312_CR24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/ana.24520","volume":"78","author":"MA Mikati","year":"2015","unstructured":"Mikati MA, Jiang Y, Carboni M et al (2015) Quinidine in the treatment of KCNT1-positive epilepsies. Ann Neurol 78:995\u2013999","journal-title":"Ann Neurol"},{"key":"2312_CR25","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ana.24598","volume":"79","author":"PF Chong","year":"2016","unstructured":"Chong PF, Nakamura R, Saitsu H et al (2016) Ineffective quinidine therapy in early onset epileptic encephalopathy with KCNT1 mutation. Ann Neurol 79:502\u2013503","journal-title":"Ann Neurol"},{"key":"2312_CR26","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1038\/ncomms3410","volume":"4","author":"SC Baraban","year":"2013","unstructured":"Baraban SC, Dinday MT, Hortopan GA (2013) Drug screening in SCN1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat Commun 4:2410","journal-title":"Nat Commun"},{"key":"2312_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww342","author":"A Griffen","year":"2017","unstructured":"Griffen A, Hamling KR, Knupp K et al (2017) Clemizole and modulators of serotonin signaling suppress seizures in Dravet syndrome. Brain. doi:\n10.1093\/brain\/aww342","journal-title":"Brain"}],"updated-by":[{"DOI":"10.1007\/s11064-017-2396-4","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T00:00:00Z","timestamp":1505952000000}}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-017-2312-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-017-2312-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-017-2312-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T01:34:23Z","timestamp":1499650463000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-017-2312-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,12]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["2312"],"URL":"https:\/\/doi.org\/10.1007\/s11064-017-2312-y","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,12]]}}}